Medicover AB (publ) (MCOV_B) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Morning everybody, it's it's John here and welcome to our Q4 results. It's another good quarter for us. We've made some good progress. We've got continuing strong performance, you know double digit growth again and we're seeing margin expansion which is Really, really pleasing. You know, the performance remains strong. We're seeing that with good demand across all of our markets and particularly from our fee for service segment. Margins are improving and good cost control in place. So we're well positioned. We predicted a bit of softness in some of our lines in the previous quarter and we have seen that and we said that it would continue for a little bit longer. But we do see the beginnings of signs of recovery, certainly in Q4. So we're watching this space as we go through to Q1. We've got continued organic growth and profitability improvements in healthcare services, particularly driven by our sports and wellness business and our ambulatory business. Our diagnostic services team, they've continued their momentum. They've got double-digit growth in all of the fee-for-service markets and really strong volume tests that have increased. So well done to the team there. It's really great to see. We predicted that our leverage would come down and we see that happening. So down at 3.1 and the board has recommended a dividend increase, which I think really reflects our progress. On the right hand side, you can see organic growth 10.6, which is really solid. We see continuing operating leverage coming through on our adjusted EBITDA, you know, plus 20, 20.9. So again, an encouraging sort of trend for us in the fourth quarter, different season, different quarter. And in terms of margin improvement, you can see that that's followed through as well with a really decent margin in...